For individuals prescribed Mounjaro for type 2 diabetes or weight management, regular monitoring should include HbA1c, fasting glucose, lipid profiles, renal function, and blood pressure, in line with NICE guidance (NG28 for type 2 diabetes, CG189 for obesity)
GLP-1 receptor agonists are incretin-based therapies that: Enhance glucose-dependent insulin secretion Suppress glucagon release Slow gastric emptying Promote satiety and weight loss Common medications include: Semaglutide Tirzepatide Dulaglutide Liraglutide Their ability to delay gastric emptying is central to both their therapeutic benefits and perioperative risks
Such convenience has also improved physician preference and patient acceptability, and net effect has increased prescription rates
PLGA nanoparticles and liposomes outperformed MSNs and GNPs due to smaller size and sustained antigenadjuvant release, with liposomes further inducing the strongest CD4 + and CD8 + T cell responses
Here, we explore what causes ED, how obesity contributes to it, and the potential role of GLP-1 medications in improving both weight and sexual health
